Modufolin (Arfolitixorin) in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer

• Status: Completed
• Trial end date: 2020-01-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose is to characterise the tolerability of Modufolin (arfolitixorin) in combination with 5-FU alone, in combination with 5-FU and Oxaliplatin, in combination with 5-FU and Irinotecan and in combination with 5-FU, Oxaliplatin and Bevacizumab.

Another purpose is to investigate 4 doses of Modufolin to identify the best dose for further assessment.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Isofol Medical AB
• Treatments: Bevacizumab; Camptothecin; Fluorouracil; Irinotecan; Oxaliplatin; Tetrahydrofolates

Criteria

Inclusion Criteria:

Advanced metastatic colorectal (Stage IV) cancer verified by biopsy